Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitor
Pharma
FDA signs off on Bayer's HER2-mutated lung cancer med Hyrnuo
placeholderBayer's Hyrnuo won an approval to treat a rare tumor type in certain patients with lung cancer, catching up to Boehringer's rival Hernexeos.
Zoey Becker
Nov 19, 2025 4:52pm
EyePoint's Duravyu bounces back with promising DME data
Oct 28, 2024 1:11pm
Clearside's CLS-AX excels in phase 2b trial, set for phase 3
Oct 9, 2024 11:47am
Takeda circles Ascentage's Scemblix challenger for up to $1.3B
Jun 14, 2024 11:30am
Boehringer Ingelheim preps for 2 upcoming oncology launches
Jun 10, 2024 8:20am
Merck and Eisai call it quits on drug combo trial in melanoma
Apr 7, 2023 9:43am
